Synthetic analog · 16 amino acids · 1,682 Da

Plecanatide studies and research data

PepBank has 24 plecanatide studies with results. All of them gave plecanatide, with 178 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 178 results and 48 papers. Newer studies from Europe PMC

Results in people

157

88% of 178 results

Results in animals

9% of 178 results

Results in lab cells

3% of 178 results

From computer models

0% of 178 results

The molecule

Plecanatide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Plecanatide is a 16-residue uroguanylin analog with two disulfide bridges. It activates guanylate cyclase-C locally in the intestine. The US label concerns constipation disorders in adults.

Kind: Synthetic analog · 16 residues
Identifiers: ChEMBLCHEMBL2103867 (opens in a new tab)PubChem CID70693500 (opens in a new tab)UNII7IK8Z952OK (opens in a new tab)DrugBankDB13170 (opens in a new tab)CAS467426-54-6
Parent: Analog of Human uroguanylinPlecanatide replaces Asp3 with Glu in mature human uroguanylin. UniProt Q16661 identifies uroguanylin at precursor residues 97–112. This is an analog relationship, not an identical endogenous sequence.
Development: Approved in the US (Trulance)An approved medicinal product exists. Availability and other indications can differ. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Guanylate cyclase CGUCY2CP25092 (opens in a new tab)	Agonist	Official prescribing information, mechanism of actionSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

16 amino acids · 2 disulfide bonds

H-

NDECELCVNV

ACTGCL

-OH

Parent: Human uroguanylin

No sequence is listed for the parent, so no alignment is shown.Plecanatide replaces Asp3 with Glu in mature human uroguanylin. UniProt Q16661 identifies uroguanylin at precursor residues 97–112. This is an analog relationship, not an identical endogenous sequence.

Properties

From identity sources

Formula: C₆₅H₁₀₄N₁₈O₂₆S₄
Molecular weight: 1,682 g/mol
Monoisotopic mass: 1,680.6252 Da

GSRS UNII 7IK8Z952OK(opens in a new tab)retrieved 2026-10-27
PubChem CID 70693500(opens in a new tab)retrieved 2026-10-27
Curated Trulance US label(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Average mass: 1,681.89 Da; Sum of ExPASy residue masses + water + 2 disulfides · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 1,680.6252 Da; Sum of ExPASy residue masses + water + 2 disulfides · ExPASy FindMod
Isoelectric point (pI): 3.42; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: −3.06; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): 0.575; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Positive: hydrophobic on average.
Extinction coefficient, 280 nm (Cys reduced): 0 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp or Tyr: absorbance at 280 nm cannot measure this peptide.
Extinction coefficient, 280 nm (all Cys as cystines): 250 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr + 125 x cystine · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 86.69; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 91.3; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 0.77 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.275; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 3.42Bjellqvist (ExPASy) 3.57IPC peptide 2.98IPC protein 3.22

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 3.42 · Net charge at pH 7.4: −3.06

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set, 2 disulfide. Calculated, not measured.

Show as table

pH	Net charge
0	1.00
1	0.99
2	0.95
3	0.54
4	−1.16
5	−2.66
6	−2.97
7	−3.02
8	−3.20
9	−3.72
10	−3.96
11	−4.00
12	−4.00
13	−4.00
14	−4.00

Composition

Hydrophobic31% (5)A L V
Negative19% (3)D E
Polar19% (3)N T
Special31% (5)C G

16 residues. Each residue counts in one class; F and W count as aromatic.

A Ala1 · 6%

I Ile0 · 0%

L Leu2 · 13%

M Met0 · 0%

V Val2 · 13%

F Phe0 · 0%

W Trp0 · 0%

Y Tyr0 · 0%

H His0 · 0%

K Lys0 · 0%

R Arg0 · 0%

D Asp1 · 6%

E Glu2 · 13%

N Asn2 · 13%

Q Gln0 · 0%

S Ser0 · 0%

T Thr1 · 6%

C Cys4 · 25%

G Gly1 · 6%

P Pro0 · 0%

3D structure

PredictedAlphaFold DB · Q16661

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Plecanatide has 16 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 70693500(opens in a new tab)

C[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CC(=O)N)C(C)C)CC(C)C)CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.145
μH, best 11-residue window: 0.275
Arrow direction: 252°
Residues: 16

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	N	0°	-0.78
2	D	100°	-0.90
3	E	200°	-0.74
4	C	300°	0.29
5	E	40°	-0.74
6	L	140°	1.06
7	C	240°	0.29
8	V	340°	1.08
9	N	80°	-0.78
10	V	180°	1.08
11	A	280°	0.62
12	C	20°	0.29
13	T	120°	-0.05
14	G	220°	0.48
15	C	320°	0.29
16	L	60°	1.06

Results by area

Plecanatide results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

24 of 48 studies have results (50%), published 2013 to 2026. Top row: every study. Bottom row: studies with results about Plecanatide, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies48 in all, 2013 to 2026

Studies with results24 in all, 2013 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Plecanatide studies on stomach and gut

96 results · people 86 · animals 6 · lab 4

Top 5 of 96 results

Overall response was 25.6% with plecanatide 3 mg versus 16.0% with placebo in IBS-C.International journal of general medicine, 2023
In adults with constipation, plecanatide 3 mg increased durable bowel response versus placebo.Therapeutic advances in gastroenterology, 2017
In mice with chemically induced colitis, plecanatide reduced colitis severity.World journal of gastrointestinal pharmacology and therapeutics, 2015
In Chinese patients with functional constipation, plecanatide increased durable CSBM response versus placebo.Drugs, 2025
In adults with constipation, plecanatide 6 mg increased durable bowel response versus placebo.Therapeutic advances in gastroenterology, 2017

Plecanatide studies on side effects

54 results · people 54 · animals 0 · lab 0

Top 5 of 54 results

In IBS-C, diarrhea caused discontinuation in 1.2% with plecanatide 3 mg versus 0 with placebo.The American journal of gastroenterology, 2018
Diarrhea occurred in 4.9% with plecanatide 3 mg versus 1.3% with placebo.Clinical and translational gastroenterology, 2023
In healthy volunteers, adverse event rates were comparable with plecanatide and placebo.Digestive diseases and sciences, 2013
FAERS contained 49 muscle spasm reports linked to suspected plecanatide exposure.Frontiers in pharmacology, 2025
In the open-label plecanatide CIC study, urinary tract infection occurred in 2.2% of patients.Current medical research and opinion, 2018

Plecanatide studies on use, access and costs

7 results · people 7 · animals 0 · lab 0

Top 5 of 7 results

Plecanatide was linked to higher discontinuation hazard than prucalopride after two months.Journal of managed care & specialty pharmacy, 2024
Medicare patients receiving plecanatide had higher adjusted total costs than those receiving linaclotide.Advances in therapy, 2025
In the plecanatide IBS-C study, 1842 of 2272 patients (81.1%) completed the study.Current medical research and opinion, 2019
Plecanatide had numerically lower days covered than prucalopride, with no significant difference.Journal of managed care & specialty pharmacy, 2024
Medicare patients receiving plecanatide had higher medical costs than those receiving linaclotide.Advances in therapy, 2025

Plecanatide studies on daily life and fitness

5 results · people 5 · animals 0 · lab 0

Top 4 of 5 results

At treatment end, plecanatide-treated CIC patients had a median satisfaction score of 4.0, indicating quite satisfied.Current medical research and opinion, 2018
In adult pharmacovigilance reports, plecanatide was linked to patient dissatisfaction.Therapie, 2025
At week 53 or treatment end, 72.4% of plecanatide-treated IBS-C patients were very or quite satisfied.Current medical research and opinion, 2019
At treatment end, plecanatide-treated CIC patients had a median continuation score of 4.0, indicating quite likely.Current medical research and opinion, 2018

Plecanatide studies on blood levels and clearance

3 results · people 3 · animals 0 · lab 0

3 results

In healthy volunteers, plecanatide absorption into blood was undetectable with the study assay.Digestive diseases and sciences, 2013
In Chinese patients with functional constipation, plasma plecanatide remained below the quantification limit.Drugs, 2025
In Chinese patients with functional constipation given plecanatide, its metabolite remained below the quantification limit.Drugs, 2025

Plecanatide studies on pain

4 results · people 2 · animals 2 · lab 0

Top 3 of 4 results

In IBS-C with moderate-to-severe bloating, plecanatide reduced abdominal pain more than placebo.Digestive diseases and sciences, 2024
In IBS-C with mild bloating, plecanatide reduced abdominal pain more than placebo.Digestive diseases and sciences, 2024
In rats, plecanatide reduced TNBS-induced abdominal contractions during colorectal distension.World journal of gastroenterology, 2018

Plecanatide studies on receptors and cell signals

5 results · people 0 · animals 4 · lab 1

Top 4 of 5 results

In mice, plecanatide activated cGMP/GC-C signaling.World journal of gastrointestinal pharmacology and therapeutics, 2017
In mice, plecanatide inhibited Wnt/β-catenin signaling.World journal of gastrointestinal pharmacology and therapeutics, 2017
In mice, intestinal GC-C expression did not change appreciably with plecanatide.World journal of gastrointestinal pharmacology and therapeutics, 2017
In mice, plecanatide increased uroguanylin transcripts in the proximal small intestine and colon.World journal of gastrointestinal pharmacology and therapeutics, 2017

Plecanatide studies on cancer

2 results · people 0 · animals 2 · lab 0

2 results

In mice with DSS-induced inflammation, plecanatide reduced polypoid, flat and indeterminate dysplasia formation.World journal of gastrointestinal pharmacology and therapeutics, 2017
In mice, plecanatide reduced proliferation.World journal of gastrointestinal pharmacology and therapeutics, 2017

Plecanatide studies on immune system and inflammation

1 result · people 0 · animals 1 · lab 0

1 result

In mice with DSS-induced inflammation, plecanatide decreased cytokine, chemokine and growth factor secretion measured in colon explants.World journal of gastrointestinal pharmacology and therapeutics, 2017

Plecanatide studies on weight and appetite

1 result · people 0 · animals 1 · lab 0

1 result

In mice with chemically induced colitis, plecanatide improved the body weight assessment.World journal of gastrointestinal pharmacology and therapeutics, 2015

Trials and papers

Plecanatide trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

14 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (14 of 14)

14 trials · 1 ongoing · 13 completed · 10 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

201520202025

Ph 2/3
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
NCT01429987
Oct 2011 to Dec 2012
Ph 2
CIBS
NCT01722318
Nov 2012 to Oct 2014
Ph 3
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
NCT01919697
Aug 2013 to Mar 2016
Ph 3
12-Week Study of Plecanatide for CIC (The CIC3 Study)
NCT01982240
Nov 2013 to Jun 2015
Ph 3
CIC
NCT02122471
Apr 2014 to Jul 2015
Ph 3
IBS-C
NCT02387359
Dec 2014 to Feb 2017
Ph 3
IBS-C
NCT02493452
Jun 2015 to Feb 2017
Ph 3
IBS-C
NCT02706483
Jan 2016 to Jun 2017
Ph 2
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
NCT03120520
Jan 2017 to 7 Sept 2018
Ph –
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
NCT03551873
21 Jun 2018 to 14 Dec 2018

14 trials · 1 ongoing · 13 completed · 10 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02387359

The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)

Bausch Health Americas, Inc.n = 1,054Dec 2014 to Feb 2017

Irritable Bowel Syndrome Characterized by Constipation

Trial page ClinicalTrials.govUpdated 20 Oct 2026

CompletedPhase 3NCT05151328

Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.n = 64818 Mar 2022 to 26 Oct 2023

Functional Constipation

Trial page ClinicalTrials.govUpdated 11 Jul 2024

CompletedPhase 3Results postedNCT02706483

Long Term Safety Study of Plecanatide

Bausch Health Americas, Inc.n = 2,272Jan 2016 to Jun 2017

Irritable Bowel Syndrome

Trial page ClinicalTrials.govUpdated 18 Aug 2020

CompletedPhase 3Results postedNCT01982240

12-Week Study of Plecanatide for CIC (The CIC3 Study)

Bausch Health Americas, Inc.n = 1,394Nov 2013 to Jun 2015

Chronic Idiopathic Constipation

Trial page ClinicalTrials.govUpdated 26 Dec 2019

CompletedPhase 3Results postedNCT01919697

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Bausch Health Americas, Inc.n = 2,370Aug 2013 to Mar 2016

Chronic Idiopathic Constipation

Trial page ClinicalTrials.govUpdated 2 Jul 2019

CompletedPhase 3Results postedNCT02493452

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

Bausch Health Americas, Inc.n = 1,135Jun 2015 to Feb 2017

Irritable Bowel Syndrome Characterized by Constipation

Trial page ClinicalTrials.govUpdated 14 Jun 2019

CompletedPhase 2/3Results postedNCT01429987

The Plecanatide Chronic Idiopathic Constipation (CIC) Study

Bausch Health Americas, Inc.n = 951Oct 2011 to Dec 2012

Chronic Idiopathic Constipation

Trial page ClinicalTrials.govUpdated 28 May 2019

CompletedPhase 3Results postedNCT02122471

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

Bausch Health Americas, Inc.n = 1,410Apr 2014 to Jul 2015

Chronic Idiopathic Constipation

Trial page ClinicalTrials.govUpdated 28 May 2019

RecruitingPhase 2NCT07723924

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

Bausch Health Americas, Inc.n = 18018 Aug 2026 to est. 18 Oct 2027

Functional Constipation (FC)

Trial page ClinicalTrials.govUpdated 7 Oct 2026

CompletedPhase 2Results postedNCT03596905

Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)

Bausch Health Americas, Inc.n = 21830 Jun 2018 to 25 Nov 2024

Irritable Bowel Syndrome With Constipation

Trial page ClinicalTrials.govUpdated 31 Dec 2025

CompletedPhase 2Results postedNCT03120520

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

Bausch Health Americas, Inc.n = 124Jan 2017 to 7 Sept 2018

Chronic Idiopathic Constipation

Trial page ClinicalTrials.govUpdated 4 Oct 2019

CompletedPhase 2Results postedNCT01722318

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Bausch Health Americas, Inc.n = 428Nov 2012 to Oct 2014

Irritable Bowel Syndrome Characterized by Constipation

Trial page ClinicalTrials.govUpdated 28 May 2019

CompletedPhase 1NCT05107219

GCC Agonist Signal in the Small Intestine

University of Wisconsin, Madisonn = 4330 Nov 2022 to 6 Feb 2026

Barrett Esophagus · Gastroesophageal Reflux Disease · Malignant Digestive System Neoplasm

Trial page ClinicalTrials.govUpdated 7 Apr 2026

CompletedPhase not statedNCT03551873

A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

Bausch Health Americas, Inc.n = 721 Jun 2018 to 14 Dec 2018

Chronic Idiopathic Constipation

Trial page ClinicalTrials.govUpdated 22 Nov 2019

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

48 studies match. Retracted studies are left out.

Showing 25 of 48 studiesquery qry_3cf030a31b62f6f74e4eaa35

Studies with results

24 studies in all, 10 on this page

Randomized controlled trial · 2018

11 results

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.

Brenner et al. 2018The American journal of gastroenterologycited by 125

PMID 29545635DOI 10.1038/s41395-018-0026-7PUB-29545635

Full text at the publisher11 results where Plecanatide was given

Publisher page See results (11)

Randomized controlled trial · 2017

10 results

A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.

Jr et al. 2017The American journal of gastroenterologycited by 108

PMID 28169285PMC5415706DOI 10.1038/ajg.2016.611PUB-28169285

Free to read · publisher termsCC BY-NC10 results where Plecanatide was given

Read at source See results (10)

Randomized controlled trial · 2013

5 results

Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses.

Shailubhai et al. 2013Digestive diseases and sciencesn = 71cited by 72

PMID 23625291DOI 10.1007/s10620-013-2684-zPUB-23625291

Full text at the publisher5 results where Plecanatide was given

Publisher page See results (5)

Randomized controlled trial · 2017

9 results

Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.

DeMicco et al. 2017Therapeutic advances in gastroenterologycited by 63

PMID 29147135PMC5673020DOI 10.1177/1756283x17734697PUB-29147135

Free to read · publisher termsCC BY-NC9 results where Plecanatide was given

Read at source See results (9)

Animal study (in vivo) · mouse · 2015

7 results

Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.

Shailubhai et al. 2015World journal of gastrointestinal pharmacology and therapeuticscited by 59

PMID 26558155PMC4635161DOI 10.4292/wjgpt.v6.i4.213PUB-26558155

Rights unknown7 results where Plecanatide was given

Source link See results (7)

Animal study (in vivo) · rat · 2018

7 results

Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models.

Boulete et al. 2018World journal of gastroenterologycited by 25

PMID 29740204PMC5937206DOI 10.3748/wjg.v24.i17.1888PUB-29740204

Free to read · publisher termsCC BY-NC7 results where Plecanatide was given

Read at source See results (7)

Animal study (in vivo) · mouse · 2017

7 results

Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc^+/Min-FCCC mice.

Chang et al. 2017World journal of gastrointestinal pharmacology and therapeuticscited by 23

PMID 28217374PMC5292606DOI 10.4292/wjgpt.v8.i1.47PUB-28217374

Free to read · publisher termsCC BY-NC7 results where Plecanatide was given

Read at source See results (7)

Non-randomized trial · 2018

10 results

Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study.

Barish et al. 2018Current medical research and opinioncited by 21

PMID 29343131DOI 10.1080/03007995.2018.1430024PUB-29343131

Full text at the publisher10 results where Plecanatide was given

Publisher page See results (10)

Randomized controlled trial · 2024

8 results

Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.

Brenner et al. 2024Digestive diseases and sciencesn = 1,104cited by 13

PMID 38594429PMC11098865DOI 10.1007/s10620-024-08330-yPUB-38594429

Free to read · publisher termsCC BY-NC8 results where Plecanatide was given

Read at source See results (8)

Randomized controlled trial · 2020

14 results

Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older.

Menees et al. 2020Clinical therapeuticsn = 4,364cited by 8

PMID 32660770DOI 10.1016/j.clinthera.2020.05.012PUB-32660770

Remes-Troche et al. 2018Revista de gastroenterologia de Mexico (English)cited by 10

PMID 29555103DOI 10.1016/j.rgmx.2017.12.005PUB-29555103

Full text at the publisher

Publisher page

PubMed tag: none · 2019

Blunted Evoked Prouroguanylin Endocrine Secretion in Chronic Constipation.

Waldman et al. 2019Clinical and translational gastroenterologycited by 8

PMID 31318728PMC6708669DOI 10.14309/ctg.0000000000000016PUB-31318728

Free to read · publisher termsCC BY-NC-ND

Read at source

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Plecanatide studies: 24 papers with results

Page 1 of 1

Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials.
Brenner DM · International journal of general medicine · 2023
Randomized controlled trial · 9 results
Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial.
Barish C · Digestive diseases and sciences · 2021
Randomized controlled trial · 7 results
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Bai T · Drugs · 2025
Randomized controlled trial · 8 results
Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
Brenner DM · The American journal of gastroenterology · 2018
Randomized controlled trial · 11 results
A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.
Miner PB Jr · The American journal of gastroenterology · 2017
Randomized controlled trial · 10 results
Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.
DeMicco M · Therapeutic advances in gastroenterology · 2017
Randomized controlled trial · 9 results
Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation.
Cash BD · Neurogastroenterology and motility · 2023
Randomized controlled trial · 6 results
The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials.
Moshiree B · Clinical therapeutics · 2022
Randomized controlled trial · 4 results
The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint.
Brenner DM · Journal of gastroenterology and hepatology · 2025
Randomized controlled trial · 3 results
Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older.
Menees SB · Clinical therapeutics · 2020
Randomized controlled trial · 14 results
Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide.
Rao SSC · Clinical and translational gastroenterology · 2023
Randomized controlled trial · 19 results
Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.
Brenner DM · Digestive diseases and sciences · 2024
Randomized controlled trial · 8 results
Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses.
Shailubhai K · Digestive diseases and sciences · 2013
Randomized controlled trial · 5 results
Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel syndrome with constipation.
Barish CF · Current medical research and opinion · 2019
Non-randomized trial · 10 results
Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study.
Barish CF · Current medical research and opinion · 2018
Non-randomized trial · 10 results
Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system.
Zhang Z · Frontiers in pharmacology · 2024
Observational study · 10 results
A pharmacovigilance study of the association between linaclotide/plecanatide and muscle spasms based on food and drug administration adverse event reporting system.
Fan X · Frontiers in pharmacology · 2025
Observational study · 2 results
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States.
Cash BD · Journal of managed care & specialty pharmacy · 2024
Observational study · 3 results
Based on the FDA Adverse Event Reporting System Database, a Study on Signal Mining of Adverse Events for Guanylate Cyclase-C Receptor Agonists.
Lei D · Hospital pharmacy · 2026
Observational study · 6 results
Drugs and patient's dissatisfaction reporting: From a disproportionality pharmacovigilance analysis to social pharmacology.
Montastruc JL · Therapie · 2025
Observational study · 1 result
Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population.
Shah E · Advances in therapy · 2025
Observational study · 2 results
Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.
Shailubhai K · World journal of gastrointestinal pharmacology and therapeutics · 2015
Animal study (in vivo) · mouse · 7 results
Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models.
Boulete IM · World journal of gastroenterology · 2018
Animal study (in vivo) · rat · 7 results
Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice.
Chang WL · World journal of gastrointestinal pharmacology and therapeutics · 2017
Animal study (in vivo) · mouse · 7 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Trulance	27 Oct 2026	dailymed.nlm.nih.gov (opens in a new tab)
EU	EMA	No product-specific central EMA authorisation was established. This does not decide national authorisations.	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Not listed as banned by WADA The substance is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

54 safety results for Plecanatide.

Human evidence· 54

Diarrhea occurred in 4.9% with plecanatide 3 mg versus 1.3% with placebo in adults with CIC.
Randomized controlled trialn = 1,762
Diarrhea incidence
4.9%
plecanatide 3 mg
Diarrhea incidence
1.3%
placebo
In Chinese patients with functional constipation, treatment-related diarrhea occurred in 4.3% with plecanatide versus 0.6% with placebo (p = 0.002).
Randomized controlled trialn = 648
Treatment-related emergent diarrhea
4.3 percent
plecanatide
Treatment-related emergent diarrhea
0.6 percent
placebo
In healthy volunteers, TEAE rates were comparable with plecanatide and placebo (24.5% versus 22.2%).
Randomized controlled trialn = 71
TEAE rate
24.5%
plecanatide
TEAE rate
22.2%
placebo
In IBS-C, diarrhea occurred in 4.3% with plecanatide 3 mg versus 1.0% with placebo.
Randomized controlled trialn not reported
diarrhea incidence
4.3%
plecanatide 3 mg
diarrhea incidence
1%
placebo
In IBS-C, diarrhea occurred in 4.0% with plecanatide 6 mg versus 1.0% with placebo.
Randomized controlled trialn not reported
diarrhea incidence
4%
plecanatide 6 mg
diarrhea incidence
1%
placebo
In IBS-C, diarrhea caused discontinuation in 1.2% with plecanatide 3 mg versus 0 with placebo.
Randomized controlled trialn not reported
discontinuation due to diarrhea
1.2%
plecanatide 3 mg
discontinuation due to diarrhea
0%
placebo
In IBS-C, diarrhea caused discontinuation in 1.4% with plecanatide 6 mg versus 0 with placebo.
Randomized controlled trialn not reported
discontinuation due to diarrhea
1.4%
plecanatide 6 mg
discontinuation due to diarrhea
0%
placebo
In CIC, diarrhea occurred in 5.9% with plecanatide 3 mg versus 1.3% with placebo.
Randomized controlled trialn not reported
Diarrhea incidence
5.9%
plecanatide 3 mg
Diarrhea incidence
1.3%
placebo

The top 24 of 54 results.

Doses studied · 28

The doses that these studies used. They are not recommendations.

3 mgHuman
Species
human
Route
Not reported
Duration
12 weeks
Design
Randomized controlled trial · n = 1,453
6 mgHuman
Species
human
Route
Not reported
Duration
12 weeks
Design
Randomized controlled trial · n = 1,452
3 mgHuman
Species
human
Route
Not reported
Duration
12 weeks
Design
Randomized controlled trial · n = 648
3 mgHuman
Species
human
Route
Not reported
Duration
12 weeks
Design
Randomized controlled trial
6 mgHuman
Species
human
Route
Not reported
Duration
12 weeks
Design
Randomized controlled trial
3 mg once dailyHuman
Species
human
Route
oral
Duration
12 weeks
Design
Randomized controlled trial

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
3 mg	Human	human	Not reported	12 weeks	Randomized controlled trial · n = 1,453
6 mg	Human	human	Not reported	12 weeks	Randomized controlled trial · n = 1,452
3 mg	Human	human	Not reported	12 weeks	Randomized controlled trial · n = 648
3 mg	Human	human	Not reported	12 weeks	Randomized controlled trial
6 mg	Human	human	Not reported	12 weeks	Randomized controlled trial
3 mg once daily	Human	human	oral	12 weeks	Randomized controlled trial

6 of 28 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000164
Peptide version: 2
Peptide hash: 7dbc1e68b48ce556…
Data version: 308560

Latest changes

28 Oct 2026UpdatedData version 304199
27 Oct 2026CreatedData version 256760

For developers

curl -s https://pepbank.io/v1/briefs/plecanatide

Evidence summary for Plecanatide: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Bowel FunctionGastrointestinal	Human: 80 results from 12 studies: 55 increase, 5 decrease, 1 no significant change, 19 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	80
Adverse eventsWhole body	Human: 38 results from 11 studies: 14 increase, 1 no significant change, 23 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	38
Gastrointestinal adverse eventsGastrointestinal	Human: 16 results from 10 studies: 11 increase, 1 decrease, 4 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	16
Bowel functionGastrointestinal	Human: 6 results from 1 study: 5 increase, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	6
Patient-reported outcomesWhole body	Human: 5 results from 3 studies: 1 increase, 4 not reported. Strongest design: Non-randomized trial	No results	No results	No results	5
PharmacokineticsPharmacology	Human: 3 results from 2 studies: 3 not reported. Strongest design: Non-randomized trial	No results	No results	No results	3
Treatment adherence and retentionWhole body	Human: 3 results from 1 study: 1 increase, 2 decrease. Strongest design: Observational study	No results	No results	No results	3
PainGastrointestinal	Human: 2 results from 1 study: 2 decrease. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 decrease. Strongest design: Animal study (in vivo)	No results	No results	4
Healthcare costs and utilizationWhole body	Human: 2 results from 1 study: 2 increase. Strongest design: Observational study	No results	No results	No results	2
Study retentionWhole body	Human: 2 results from 2 studies: 2 not reported. Strongest design: Non-randomized trial	No results	No results	No results	2
Gastrointestinal protectionGastrointestinal	No results	Animal: 6 results from 2 studies: 3 decrease, 3 no significant change. Strongest design: Animal study (in vivo)	Lab: 4 results from 1 study: 1 decrease, 1 no significant change, 2 not reported. Strongest design: In vitro (cells)	No results	10
Receptor activity and mechanismGastrointestinal	No results	Animal: 4 results from 1 study: 2 increase, 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 increase. Strongest design: In vitro (cells)	No results	5

Outcome group	Human	Animal	Lab	Computer model	Total
Bowel FunctionGastrointestinal	Human: 80 results from 12 studies: 55 increase, 5 decrease, 1 no significant change, 19 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	80
Adverse eventsWhole body	Human: 38 results from 11 studies: 14 increase, 1 no significant change, 23 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	38
Gastrointestinal adverse eventsGastrointestinal	Human: 16 results from 10 studies: 11 increase, 1 decrease, 4 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	16
Bowel functionGastrointestinal	Human: 6 results from 1 study: 5 increase, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	6
Patient-reported outcomesWhole body	Human: 5 results from 3 studies: 1 increase, 4 not reported. Strongest design: Non-randomized trial	No results	No results	No results	5
PharmacokineticsPharmacology	Human: 3 results from 2 studies: 3 not reported. Strongest design: Non-randomized trial	No results	No results	No results	3
Treatment adherence and retentionWhole body	Human: 3 results from 1 study: 1 increase, 2 decrease. Strongest design: Observational study	No results	No results	No results	3
PainGastrointestinal	Human: 2 results from 1 study: 2 decrease. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 decrease. Strongest design: Animal study (in vivo)	No results	No results	4
Healthcare costs and utilizationWhole body	Human: 2 results from 1 study: 2 increase. Strongest design: Observational study	No results	No results	No results	2
Study retentionWhole body	Human: 2 results from 2 studies: 2 not reported. Strongest design: Non-randomized trial	No results	No results	No results	2
Gastrointestinal protectionGastrointestinal	No results	Animal: 6 results from 2 studies: 3 decrease, 3 no significant change. Strongest design: Animal study (in vivo)	Lab: 4 results from 1 study: 1 decrease, 1 no significant change, 2 not reported. Strongest design: In vitro (cells)	No results	10
Receptor activity and mechanismGastrointestinal	No results	Animal: 4 results from 1 study: 2 increase, 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 increase. Strongest design: In vitro (cells)	No results	5

Plecanatide studies and research data

Plecanatide identity

Targets

Sequence and structure

Sequence

Parent: Human uroguanylin

Properties

Net charge by pH

Composition

3D structure

2D structure

Helical wheel

Plecanatide results by year and outcome

What the studies measured

Plecanatide studies on stomach and gut

Plecanatide studies on side effects

Plecanatide studies on use, access and costs

Plecanatide studies on daily life and fitness

Plecanatide studies on blood levels and clearance

Plecanatide studies on pain

Plecanatide studies on receptors and cell signals

Plecanatide studies on cancer

Plecanatide studies on immune system and inflammation

Plecanatide studies on weight and appetite

Plecanatide trials

The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)

Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation

Long Term Safety Study of Plecanatide

12-Week Study of Plecanatide for CIC (The CIC3 Study)

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

The Plecanatide Chronic Idiopathic Constipation (CIC) Study

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

GCC Agonist Signal in the Small Intestine

A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

Papers

Studies with results

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.

A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.

Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses.

Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.

Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.

Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models.

Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice.

Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study.

Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.

Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older.

More studies

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.

AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.

Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis.

Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.

Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis.

Defibrotide.

Plecanatide (Trulance) for Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.

Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.

Eteplirsen.

Liquid-Phase Total Synthesis of Plecanatide Aided by Diphenylphosphinyloxyl Diphenyl Ketone (DDK) Derivatives.

Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.

Pharmacotherapeutic advances for chronic idiopathic constipation in adults.

The Mexican consensus on chronic constipation.

Blunted Evoked Prouroguanylin Endocrine Secretion in Chronic Constipation.

Newer studies

Plecanatide studies: 24 papers with results

Regulatory and safety

Human evidence· 54

Doses studied · 28

Data and API

Peptide

Latest changes

For developers

Related peptides

Plecanatide results by year and outcome

Plecanatide studies on stomach and gut

Plecanatide studies on side effects

Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc^+/Min-FCCC mice.

Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc^+/Min-FCCC mice.